Profil bibliographique

Paul K. Paik

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

462Publications signalées

19246Citations signalées

1Affiliations récentes

Institutions déclarées

Memorial Sloan Kettering Cancer Center

Domaines associés

Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentCancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Publications récentes

Accès ouvert 2026 articleOpenAlex

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial

Narek Shaverdian, Michael Offin, Nicolas Toumbacaris, Jasme Lee et autres

0 citationsNature Communications

2026 erratumOpenAlex

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Deborah B. Doroshow, Ticiana A. Leal, Saiama N. Waqar, Hossein Borghaei et autres

0 citationsJournal of Clinical Oncology

2026 articleOpenAlex

Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Deborah B. Doroshow, Ticiana A. Leal, Saiama N. Waqar, Hossein Borghaei et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Profiling patients with MET exon 14 ( MET ex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.

Paul K. Paik, Egbert F. Smit, Hélène Senellart, Remi Veillon et autres

0 citationsJournal of Clinical Oncology

2026 articleOpenAlex

Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.

Paul K. Paik, Koichi Goto, A Spira, Wade T. Iams et autres

0 citationsJournal of Clinical Oncology

2026 articleOpenAlex

Indirect comparison of the effectiveness of tepotinib and immunotherapy in NSCLC with METex14 skipping alterations: Final propensity-scored analysis of eight pooled real-world datasets (TOGETHER) vs the VISION trial.

Florian Guisier, Laurent Greillier, Christos Chouaid, Petros Christopoulos et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

PP01.28: Treatment Sequencing of Tepotinib in Patients With MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Outcomes From ≥3 Years Follow-Up of the VISION Study

Paul K. Paik, Enriqueta Felip, Egbert F. Smit, Remi Veillon et autres

0 citationsJournal of Thoracic Oncology

2026 conference-abstractOpenAlex

PP01.27: Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) From the VISION Study: ≥3-Year Follow-Up Outcomes

Paul K. Paik, Remi Veillon, Alexis B. Cortot, Roberto Ferrara et autres

0 citationsJournal of Thoracic Oncology

2026 conference-abstractOpenAlex

PP01.23: Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: ≥3-Years Follow-Up of VISION

Paul K. Paik, Roberto Ferrara, Remi Veillon, Xiuning Le et autres

0 citationsJournal of Thoracic Oncology

2026 conference-abstractOpenAlex

PP01.29: Long-Term Outcomes with Tepotinib for Clinically Relevant Subgroups of Patients with MET Exon 14 (METex14) Skipping NSCLC in the VISION Study: A ≥3-Year Follow-Up

Paul K. Paik, Roberto Ferrara, Enriqueta Felip, Egbert F. Smit et autres

0 citationsJournal of Thoracic Oncology

Accès ouvert 2026 articleOpenAlex

Health-Related Quality of Life (HRQoL) with Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) with Brain, Liver, Adrenal, or Bone Metastases in the Phase II VISION Trial

Vaibhav Saxena, Niels Reinmuth, Julien Mazières, Sanjay Popat et autres

0 citationsIndian Journal of Medical and Paediatric Oncology

Accès ouvert 2025 articleOpenAlex

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry

Sara A. Walton, Justin J. Kim, Francesco Paoloni, Jean W. Liew et autres

2 citationsJCO Precision Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.